Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

352 Press Releases
DateTitleCompany
28 Jun 13 Pfizer Declares 24-Cent Third-Quarter 2013 Dividend Pfizer Inc.,
Published by
Business Wire
27 Jun 13 Pfizer Announces Final Results of Zoetis Exchange Offer Pfizer Inc.,
Published by
Business Wire
25 Jun 13 Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts Pfizer Inc.,
Published by
Business Wire
12 Jun 13 Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent Pfizer Inc.,
Published by
Business Wire
29 May 13 Pfizer Prices $4.0 Billion Debt Offering Pfizer Inc.,
Published by
Business Wire
25 Apr 13 Top-Line Data Show Celecoxib Met Primary Objective In Clinical Trial To Evaluate The Effects On Blood Pressure In Pediatric Patients With Juvenile Idiopathic Arthritis Pfizer Inc.,
Published by
Business Wire
19 Apr 13 Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders Pfizer Inc.,
Published by
Business Wire
26 Mar 13 Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts Pfizer Inc.,
Published by
Business Wire
25 Mar 13 XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA) Pfizer Inc.,
Published by
Business Wire
05 Mar 13 United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex® (celecoxib capsules) Pfizer Inc.,
Published by
Business Wire
21 Feb 13 Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures Pfizer Inc.,
Published by
Business Wire
01 Feb 13 Pfizer Inc. Issues Statement on ZoetisTM IPO Pfizer Inc.,
Published by
Business Wire
31 Jan 13 Pfizer Wins RAPAMUNE® Patent Case in Delaware District Court Pfizer Inc.,
Published by
Business Wire
29 Jan 13 Pfizer Reports Fourth-Quarter and Full-Year 2012 Results; Provides 2013 Financial Guidance Pfizer Inc.,
Published by
Business Wire
26 Jan 13 Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease Pfizer Inc.,
Published by
Business Wire
24 Jan 13 Study Shows Higher Dose Of Toviaz® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder Pfizer Inc.,
Published by
Business Wire
24 Jan 13 Pfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of PRISTIQ® (desvenlafaxine) For The Treatment Of Major Depressive Disorder (MDD) In Adults Pfizer Inc.,
Published by
Business Wire
24 Jan 13 CHANTIX® (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX Pfizer Inc.,
Published by
Business Wire
22 Jan 13 Pfizer Partnership Organizations Significantly Benefit From Pfizer’s Global Health Fellows Program Pfizer Inc.,
Published by
Business Wire
14 Jan 13 Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States Pfizer Inc.,
Published by
Business Wire
08 Jan 13 Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease Pfizer Inc.,
Published by
Business Wire
02 Jan 13 U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation Pfizer Inc.,
Published by
Business Wire
18 Dec 12 Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts Pfizer Inc.,
Published by
Business Wire
17 Dec 12 Pfizer Declares First-Quarter 2013 Dividend Pfizer Inc.,
Published by
Business Wire
14 Dec 12 U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis Pfizer Inc.,
Published by
Business Wire
09 Dec 12 ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment Pfizer Inc.,
Published by
Business Wire
05 Dec 12 Tanzania Expands Immunization Program To Include Pfizer’s Prevenar 13 For Prevention Of Pneumococcal Disease Pfizer Inc.,
Published by
Business Wire
05 Dec 12 Pfizer Presents Phase 2 Data Showing Investigational Therapy PD-0332991 Plus Letrozole Significantly Improved Progression Free Survival Compared With Letrozole Alone In Patients With ER Positive, HER2 Negative Advanced Breast Cancer Pfizer Inc.,
Published by
Business Wire
01 Dec 12 Pfizer Completes Sale of Nutrition Business to Nestlé Pfizer Inc.,
Published by
Business Wire
26 Nov 12 Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013 Pfizer Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.